Japan’s Takeda to buy psoriasis drug in up to $6 bln deal with Nimbus
Japan’s Takeda to buy psoriasis drug in up to $6 bln deal with Nimbus
Dec 13 (Reuters) – Japan’s Takeda Pharmaceutical (4502.T) said on Tuesday it would acquire Nimbus Therapeutics’ drug being developed to treat autoimmune conditions such as psoriasis in up to $6 billion deal.
The treatment will strengthen the company’s pipeline of drugs for diseases where the immune system attacks healthy cells in the body by mistake.
Takeda will make $4 billion in upfront payment to Nimbus and pay an additional $2 billion subject to certain sales milestones.
Reporting by Khushi Mandowara Editing by Vinay Dwivedi
Our Standards: The Thomson Reuters Trust Principles.
Source: Reuters
